ClinConnect ClinConnect Logo
Search / Trial NCT05889494

Autologous Whole Blood Management for Transfusion Reduction in Adult Cardiac Surgery Patients

Launched by UNIVERSITY OF ALBERTA · May 25, 2023

Trial Information

Current as of June 26, 2025

Recruiting

Keywords

Cardiac Surgery Postoperative Coagulopathy Autologous Whole Blood Transfusion Acute Normovolemic Hemodilution Intraoperative Autologous Transfusion

ClinConnect Summary

This clinical trial is looking at a new way to manage blood loss during heart surgery by using a patient’s own blood instead of blood from donors. The main goal is to see if using your own blood can reduce the need for donated blood, lower the amount of bleeding, and decrease complications after surgery. In this study, participants will be randomly assigned to one of two groups: one group will donate blood to themselves during the operation and receive it after surgery, while the other group will receive blood products from other donors.

To be eligible for this trial, you need to be an adult who is having heart surgery at the Mazankowski Alberta Heart Institute and at high risk for bleeding complications. Some key criteria for participation include being 18 years or older, but not older than 85, and not having certain medical conditions like severe heart or kidney issues. If you decide to participate, you can expect close monitoring during and after your surgery to compare the effectiveness of the two blood management methods. This study aims to improve care for future heart surgery patients, making it an important step in advancing medical practices.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Adult (≥18 yr)
  • Surgical patients at the Mazankowski Alberta Heart Institute
  • High risk for acquired coagulopathy
  • Exclusion Criteria:
  • Left ventricular ejection fraction \<20%
  • Impaired renal function
  • Preoperative anemia (hematocrit \< 30%)
  • Abnormal coagulation studies or platelet function
  • Presence of hemoglobinopathy
  • Platelet count \< 120 10\*9/L
  • Non-heparin based CPB anticoagulation
  • Presence of carotid stenosis (≥70%)
  • Presence of bacteremia/endocarditis
  • Age \> 85 yr
  • Weight \< 55 kg
  • Hepatic failure/dysfunction
  • Pregnancy
  • Chronic lung disease on home O2
  • Acute respiratory failure
  • Acute coronary syndromes
  • Emergency surgery

About University Of Alberta

The University of Alberta, a leading research institution in Canada, is dedicated to advancing healthcare through innovative clinical trials. With a strong commitment to scientific excellence and community health, the university facilitates cutting-edge research across various medical disciplines. Its interdisciplinary approach fosters collaboration among researchers, clinicians, and students, ensuring that clinical trials are designed and conducted with the utmost rigor and ethical standards. By leveraging its extensive resources and expertise, the University of Alberta aims to translate research findings into meaningful advancements in patient care and public health.

Locations

Edmonton, Alberta, Canada

Patients applied

0 patients applied

Trial Officials

Angela R Neufeld, MD

Principal Investigator

University of Alberta

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported